GPT and metabolic dysfunction-associated steatotic liver disease: In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).